Rosuvastatin-GX rosuvastatin (as calcium) 20 mg tablet blister pack

국가: 오스트레일리아

언어: 영어

출처: Department of Health (Therapeutic Goods Administration)

유효 성분:

rosuvastatin calcium, Quantity: 20.84 mg

제공처:

Medis Pharma Pty Ltd

INN (International Name):

Rosuvastatin calcium

약제 형태:

Tablet, film coated

구성:

Excipient Ingredients: lactose monohydrate; crospovidone; microcrystalline cellulose; magnesium stearate; calcium hydrogen phosphate dihydrate; titanium dioxide; hypromellose; triacetin; macrogol 3350; cochineal

관리 경로:

Oral

패키지 단위:

30 tablets

처방전 유형:

(S4) Prescription Only Medicine

치료 징후:

Rosuvastatin should be used as an adjunct to diet when the response to diet and exercise is inadequate. Prevention of Cardiovascular Events. Rosuvastatin is indicated for prevention of major cardiovascular events in men greater than or equal to 50 years old and women greater than or equal to 60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low HDL-C, smoking, or a family history of premature coronary heart disease). Rosuvastatin is indicated to: - Reduce the risk of nonfatal myocardial infarction. - Reduce the risk of nonfatal stroke. - Reduce the risk of coronary artery revascularisation procedures. In patients with hypercholesterolaemia: Rosuvastatin is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia). Prior to initiating therapy with rosuvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

제품 요약:

Visual Identification: Round, pink, biconvex tablet debossed with 'ST 3' on one side; Container Type: Blister Pack; Container Material: PVC/PVDC/Al; Container Life Time: 2 Years; Container Temperature: Store below 30 degrees Celsius

승인 상태:

Licence status A

승인 날짜:

2014-09-19